.biofargo-table-wrapper {overflow-x: auto;margin: 20px 0;-webkit-overflow-scrolling: touch;}.biofargo-spec-table {width: 100%;border-collapse: collapse;border: 1px solid #dee2e6;min-width: 600px;background: #fff;}.biofargo-spec-table th,.biofargo-spec-table td {border: 1px solid #dee2e6;padding: 12px;vertical-align: middle;white-space: normal;word-break: break-word;}@media (max-width: 600px) {.biofargo-table-wrapper {border: 1px solid #eee;border-radius: 8px;padding: 6px;background: #fff;}.biofargo-spec-table {min-width: 720px;}} Description ST2 (Suppression of Tumorigenicity 2) is a receptor for interleukin-33 (IL-33), and its soluble form (sST2) is an important prognostic marker for heart failure and myocardial fibrosis. Specifications Product Details Source Human Expression Host Mammalian cell Molecular Mass 36 kDa Formulation Purified, Liquid Purification >95% Buffer PBS, 5% Mannital, 0.01% Tween 80, pH7.4 Storage For long term storage, the product should be stored at -20°C or lower. Validity 3 years Instructions for Use Dissolve the lyophilized powder in an appropriate sterile buffer in a sterile environment before use. Prepare and dilute the solution according to experimental requirements to ensure accurate and reproducible results. Do not mix with other similar products to avoid cross-reactivity and potential interference. Cautions • Research Use Only: This product is not suitable for clinical diagnostics or therapeutic applications. • Preservation: Handle according to instructions to preserve its activity and stability. • Support: Contact our technical support team if you encounter any issues or questions. Documents 📄 Download COA 📄 Download MSDS
